Trusted brands in one place
Clinically proven for weight loss
Doctor-guided programs
No in-person appointments needed
Trusted brands in one place
Clinically proven for weight loss
Doctor-guided programs
No in-person appointments needed

Explore GLP-1's
News & Updates

Learn more about GLP'-1's latest news & updates

Explore By Category

All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oral Wegovy Hits 5M Prescriptions: What It Means
News & Updates

Oral Wegovy Hits 5M Prescriptions: What It Means

Oral semaglutide for weight loss has crossed 5 million prescriptions, pushing Novo Nordisk to raise its 2026 financial outlook. For patients considering GLP-1 therapy, this milestone raises practical questions about access, cost, and how the pill compares to the injectable version of Wegovy.

Read More
Mounjaro Weight Regain: What Really Happens
Health and Wellness

Mounjaro Weight Regain: What Really Happens

Weight regain after stopping Mounjaro (tirzepatide) is a real and well-documented pattern that affects many patients. This article explains the biology behind it, what recent public cases reveal, and the practical steps you can take to protect your results long-term.

Read More
GLP-1 Drugs Boost Women's Employment by 27 Points
Women's Health

GLP-1 Drugs Boost Women's Employment by 27 Points

A Harvard study found that women taking GLP-1 weight-loss medications saw a 27-percentage-point increase in employment rates, an effect larger than the gap between college and non-college graduates. The findings suggest these medications may do more than change the number on the scale. Here's what the research means for women weighing their options.

Read More
What Happens When You Stop GLP-1 Medications
Patient Guides

What Happens When You Stop GLP-1 Medications

Most people who stop taking GLP-1 medications regain a significant portion of their lost weight within months. This article explains what happens in your body when you stop, why it happens, and what you can do about it. Whether you're pausing due to cost, side effects, or supply issues, this guide helps you plan smarter.

Read More
Bank of America Spends $250M on GLP-1s for Employees
News & Updates

Bank of America Spends $250M on GLP-1s for Employees

Bank of America's CEO revealed the company spends $250 million annually on GLP-1 medications for its workforce. This signals a major shift in how employers view weight loss drugs, and it has real implications for patients navigating coverage and costs.

Read More
Wegovy Pill Coming to Europe: What It Means
News & Updates

Wegovy Pill Coming to Europe: What It Means

Novo Nordisk is rolling out an oral version of Wegovy (semaglutide) in its first European Union country, a significant step for weight loss treatment. This article breaks down what the pill is, how it compares to the injectable, and what it could mean for US patients watching closely.

Read More
Amazon Pharmacy Now Delivers GLP-1 Medications
News & Updates

Amazon Pharmacy Now Delivers GLP-1 Medications

Amazon Pharmacy has launched a dedicated GLP-1 delivery service, giving patients a new way to access weight loss medications like semaglutide and tirzepatide. This guide breaks down what the service offers, how pricing compares, and what to consider before switching from your current pharmacy. Understanding your options has never been more important.

Read More
Oral Wegovy: What the Rollout Means for You
GLP-1 Agonists

Oral Wegovy: What the Rollout Means for You

Novo Nordisk is moving forward with an oral version of semaglutide for weight loss, and patients are paying close attention. This article breaks down what we know about the oral Wegovy rollout, how it compares to the injectable, and what questions you should ask your doctor before making any decisions.

Read More
GLP-1 Drugs and MACE Risk: What Patients Should Know
Patient Guides

GLP-1 Drugs and MACE Risk: What Patients Should Know

Emerging evidence suggests GLP-1 receptor agonists may reduce the risk of major adverse cardiovascular events (MACE) in high-risk patients. This article breaks down what the research means, who stands to benefit most, and how this could influence your treatment decisions.

Read More